Tecan Group AG (0QLN.L)

CHF 140.26

(-2.19%)

EBITDA Summary of Tecan Group AG

  • Tecan Group AG's latest annual EBITDA in 2023 was 205.57 Million CHF , down -5.85% from previous year.
  • Tecan Group AG's latest quarterly EBITDA in 2024 Q2 was 52.92 Million CHF , down 0.0% from previous quarter.
  • Tecan Group AG reported an annual EBITDA of 210.85 Million CHF in 2022, up 6.41% from previous year.
  • Tecan Group AG reported an annual EBITDA of 201.21 Million CHF in 2021, up 26.34% from previous year.
  • Tecan Group AG reported a quarterly EBITDA of 94.57 Million CHF for 2023 Q2, down 0.0% from previous quarter.
  • Tecan Group AG reported a quarterly EBITDA of N/A for 2023 FY, down -5.85% from previous quarter.

Annual EBITDA Chart of Tecan Group AG (2023 - 2002)

Historical Annual EBITDA of Tecan Group AG (2023 - 2002)

Year EBITDA EBITDA Growth
2023 205.57 Million CHF -5.85%
2022 210.85 Million CHF 6.41%
2021 201.21 Million CHF 26.34%
2020 154.98 Million CHF 29.07%
2019 117.69 Million CHF 24.1%
2018 105.64 Million CHF 7.18%
2017 92.29 Million CHF 19.01%
2016 86.66 Million CHF 4.59%
2015 74.14 Million CHF 15.12%
2014 64.4 Million CHF 5.56%
2013 61.01 Million CHF -1.85%
2012 63.08 Million CHF -1.0%
2011 62.76 Million CHF 6.32%
2010 59.05 Million CHF -17.45%
2009 70.22 Million CHF -19.01%
2008 74.09 Million CHF 24.24%
2007 75.35 Million CHF 14.64%
2006 64.21 Million CHF 84.41%
2005 33.25 Million CHF 14.69%
2004 29.4 Million CHF -31.53%
2003 42.82 Million CHF -27.44%
2002 59.02 Million CHF 0.0%

Peer EBITDA Comparison of Tecan Group AG

Name EBITDA EBITDA Difference
Relief Therapeutics Holding AG -108.2 Million CHF 289.991%
Santhera Pharmaceuticals Holding AG 79.17 Million CHF -159.648%
Basilea Pharmaceutica AG 29.49 Million CHF -596.979%
Bachem Holding AG 163.27 Million CHF -25.906%
Siegfried Holding AG 241.21 Million CHF 14.777%
Molecular Partners AG -59.51 Million CHF 445.415%